#AUA14 - An exploratory analysis of the Genomic Prostate Score as a predictor of local or metastatic progression in men who experience biochemical recurrence after surgery for organ-confined prostate cancer - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Magi-Galluzzi’s group re-analyzed their radical prostatectomy (RP) cohort (127 patients with and 374 without clinical recurrence (CR)) to evaluate if GPS predicts CR after biochemical recurrence (BCR) and also to assess the impact of salvage therapies. These men had all undergone RP for T1 and T2 disease. Gene expression was measured in fixed paraffin-embedded tumor specimens by RT-PCR. GPS was assessed in the dominant Gleason pattern from RPs using the genes and algorithm from the validation study. BCR was defined as two successive PSA > 0.2 ng/ml. Analysis used Cox proportional hazards models with left truncation adjustment for the time between RP and BCR.

auaThey found that 185 men experienced BCR, of which 53% (98 patients) developed CR (79% metastases). They performed 3 sub-analyses: 88 men who received salvage androgen deprivation therapy (ADT) [49 CRs (56%)], 57 men who received salvage radiation (XRT) [26 CRs (46%)], and 69 men who received no salvage therapy [42 CRs (61%)]. GPS was predictive of CR in all groups in univariate (HR= 2.06, p < 0.001), and remained significant after adjusting for Gleason score (GS ≤ 7 vs GS ≥ 8) or pT stage. In univariate analysis, GPS was also predictive of CR in men within each subset: salvage ADT (HR= 2.04, p = 0.021), salvage XRT (HR=2.14, p = 0.027), and no salvage therapy (HR= 1.92, p = 0.011). The GPS components that were predictive of CR were androgen genes for ADT (p = 0.01), stromal response and androgen gene groups for XRT (p < 0.015), and cellular organization genes for men receiving no salvage therapy (p < 0.001).

The GPS (a biopsy-based gene expression assay) has been shown, by different institutions, to be a predictor of adverse pathology at the time RP. Although external validation and further studies are needed, the presented data here suggests that GPS, independent of salvage therapy, can predict risk of CR for those men who show BCR after surgery.

Presented by Cristina Magi-Galluzzi, MD, PhD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Cleveland Clinic, Cleveland, OH USA

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Annual Virtual Meeting / Oct 17
  • 2020 Annual Congress / October 10 - 11
  • 2020 Annual Meeting / October 1-3
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland